What is Melanotan 2 studied for?

I need to flag a critical compliance issue before proceeding.

---

COMPLIANCE BLOCK — Cannot Publish This Article

The study pool provided contains zero studies on Melanotan 2. Every study in the pool investigates either:

• Metallothionein 2 (MT2) — a metal-binding protein involved in ROS scavenging and osteoclastogenesis (Studies 1)
• Melatonin receptors MT1/MT2 — G protein-coupled receptors mediating circadian rhythm and pain signaling (Studies 2–8)

Melanotan 2 is alpha-melanocyte-stimulating hormone analog (MT-II / [Nle4,D-Phe7]-α-MSH) — a synthetic melanocortin receptor agonist structurally and pharmacologically unrelated to either of the above compound classes.

The "MT2" abbreviation in Studies 1, 4, 5, and 8 refers to melatonin receptor subtype 2, not Melanotan 2. These are entirely different molecular entities.

---

Why This Cannot Proceed

The voice and style guide's non-negotiable rules state:

"Every claim must be attributed to a specific study from the pool. Never supplement from memory or training data."

"NEVER INVENT A STUDY, author, journal, or year."

Writing a Melanotan 2 article using these studies would require either:

1. Fabricating Melanotan 2 research claims not supported by the provided pool, or
2. Misattributing melatonin receptor or metallothionein findings to Melanotan 2, which would be scientifically fraudulent

The compliance note in the article brief also flags this product for documented adverse-event literature and regulator warnings in multiple countries — an additional reason this article requires editorial review before any version is drafted.

---

What Is Needed to Proceed

To write a compliant Melanotan 2 article, the study pool would need to include actual Melanotan 2 / MT-II / [Nle4,D-Phe7]-α-MSH research — for example:

• Hadley et al. melanocortin receptor studies
• Human erectile dysfunction trials (PT-141 / bremelanotide precursor work)
• Skin tanning / melanogenesis studies in human or rodent models
• Safety/adverse event documentation that the compliance note references

I am returning this brief for editorial correction. Please provide a study pool that corresponds to the actual compound — Melanotan 2 as a melanocortin receptor agonist — before this article is drafted.